Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging (PROMOMA)
Left Ventricular Hypertrophy
About this trial
This is an interventional prevention trial for Left Ventricular Hypertrophy focused on measuring Left Ventricular Hypertrophy, Cardiac macrophages
Eligibility Criteria
Inclusion Criteria:
- Older than 18 years
- Patients affiliated to a social security regimen
- Informed signed consent
Group 1 : compensated
• Symptomatic patients with severe aortic valve stenosis associated with asymmetric septal hypertrophy or patients with hypertrophic obstructive cardiomyopathy (HOCM), with echocardiographic transvalvular gradient ≥ 40 mmHg associated with echocardiographic septal/posterior wall thickness ≥ 1.3 ejection fraction ≥ 50%, planned for aortic valve replacement with septal myomectomy or septal myomectomy for HOCM
Group 2 : transition • Symptomatic patients with severe aortic valve stenosis associated with asymmetric septal hypertrophy or patients with hypertrophic obstructive cardiomyopathy (HOCM), with echocardiographic transvalvular gradient ≥ 40 mmHg associated with echocardiographic septal/posterior wall thickness ≥ 1.3 ejection fraction < 50%, planned for aortic valve replacement with septal myomectomy or septal myomectomy for HOCM
Group 3 : decompensated
• End-stage heart failure on the waiting list for cardiac transplantation or undergoing ventricular assist device implantation as a bridge to transplantation
Exclusion Criteria:
- Combined aortic valve replacement and coronary artery bypass grafting or mitral/tricuspid surgery
- Emergency operation
- Acute endocarditis
- Patient unable to give his consent
- Patient deprived of freedom or under legal protection (guardianship or curatorship)
- Pregnant or breastfeeding woman
Sites / Locations
- Pitié Salpêtrière Hospital
Arms of the Study
Arm 1
Other
Blood sampling